Ask AI
SC ICI Considerations

CE

SC ICI Delivery Strategies: Practical Considerations for SC Immunotherapies

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 09, 2026

Expiration: January 08, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Kelly Romo, PharmD, BCOP, and Shawna Kraft, PharmD, BCOP, discuss supporting clinical data for the use of subcutaneous (SC) vs intravenous (IV) immune checkpoint inhibitors (ICIs) in patients with solid tumors.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with cancer do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting:

How would you counsel a patient about SC immunotherapy compared with IV formulation?

According to experts, which pharmacy action best supports safe implementation of SC ICI therapy?